Synthesis of iron oxide nanocrystals functionalized with hyaluronic acid and I-cetuximab for targeted combined (radio-photothermal) treatment of HepG2 cells.

Surface coating of NIR-plasmonic iron oxide magnetic nanocrystals (FeO MNCs) with natural polysaccharides is a promising strategy for increasing their uptake by cancer cells. In this work, chitosan-coated magnetic nanocrystals (FeO@CS MNCs) were prepared and subsequently chemically conjugated with hyaluronic acid (HA). The cellular uptake of MNCs post treatment of HepG2 cells with the synthesized (FeO@CS MNCs) and (FeO@CS-HA MNCs) was 18.

A novel gold-polymer-antibody conjugate for targeted (radio-photothermal) treatment of HepG2 cells.

Localization of the near-infrared (NIR) plasmonic nanoparticles at the tumor sites is essential for safe and efficient photothermal therapy of cancer. In this work, two biocompatible polymers: modified poly(ethylene glycol) (PEG) and branched polyethyleneimine (bPEI) were used to bind plasmonic hollow gold nanospheres (HAuNS) to the tumor-specific antibody, atezolizumab (ATZ). The photo-immunoconjugate (HAuNS-PEI-PEG-ATZ) was prepared a simple and cost-effective procedure.

Radiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma.

The goal of this article was to develop a new therapeutic strategy based on nanotechnology for multiple myeloma (MM) treatment which shows a synergism of different mechanisms. In this concern, 12.9 nm-sized silver nanoparticles (AgNPs) were prepared and functionalized with Isatuximab, anti-MM monoclonal antibody (mAb).

Targeted photoimmunotherapy based on photosensitizer-antibody conjugates for multiple myeloma treatment.

Despite the high in vitro efficacy of photodynamic therapeutics, lack of tumor targeting significantly reduces their in vivo efficacy and thus limits their clinical use. Photoimmunotherapy (PIT) is a new synthetic strategy to target and treat cancer by photodynamic therapy (PDT). In this study, we describe design and synthesis of a third-generation photosensitizer comprising a PEGylated-phthalocyanine star-polymer photosensitizer that covalently bound to a myeloma tumor-selective antibody (MAb) via the carbodiimide chemistry.